Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828556 | 0.79 | NR2E1 (0.43) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL22199020 | 0.79 | CYP11B2 (0.43) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL7419050 | 0.78 | CYP1A2 (0.41) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL7419051 | 0.78 | CYP1A2 (0.41) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL1903855 | 0.76 | GRIA1 (0.42) | CYP1A2 | |
| SCHEMBL22199045 | 0.76 | USP30 (0.47) | USP30NR2E1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13610422 | 0.73 | MAOA (0.38) | CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL12676114 | 0.73 | ALDH1A1 (0.44) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL1162746 | 0.71 | CYP1A2 (0.55) | USP30NR2E1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9699728 | 0.70 | NR2E1 (0.46) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | OPRM1, OPRD1, HTR3C | USP30 2936/4885NR2E1 428/4885CYP1A2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.